A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder

开始日期2027-01-01

申办/合作机构-

NCT05455996

/ Not yet recruiting临床2期IIT

An Open Label Study to Treat Post-Traumatic Stress in Frontline Healthcare Workers and First Responders Using MDMA-Assisted Therapy

The purpose of this study is to assess the safety and efficacy of MDMA-Assisted Therapy on Frontline Health Care Workers and First Responders suffering from symptoms of Post-Traumatic Stress.

开始日期2026-10-01

申办/合作机构

Nautilus Sanctuary

NCT06066853

/ Recruiting早期临床1期IIT

Hyperscan Neuroimaging to Reveal the Brain Mechanisms Supporting Analgesia Following MDMA-assisted Therapy for Fibromyalgia

Fibromyalgia is a debilitating chronic pain disorder. Based on prior research with MDMA, it can be hypothesized MDMA-assisted therapy in fibromyalgia patients may increase the range of positive emotions, interpersonal trust, and heighten the state of empathic rapport that can lead to an enhanced patient-clinician interaction and to initiate reattribution processes targeting dysfunctional thoughts towards pain. Therapeutic alliance, i.e. a positive patient-clinician relationship, is already acknowledged as an essential component for MDMA-assisted therapy. Despite its importance, the patient-clinician interaction and the neuroscience supporting patient/clinician therapeutic alliance has received almost no attention in MDMA research. The investigators will examine the potential therapeutic benefit of MDMA-assisted therapy for fibromyalgia. Additionally, this study will also target secondary objectives including the investigation of the clinical and physiological response (i.e. brain-to-brain concordance) supporting enhanced patient-clinician therapeutic alliance in fibromyalgia patients. The study includes two Experimental Sessions of therapy with MDMA combined with neuroimaging, along integrative therapy, baseline neuroimaging, and a 3 month follow up.

开始日期2026-07-01

申办/合作机构

The Spaulding Rehabilitation Hospital Corp.

[+1]

100 项与亚甲二氧甲基苯丙胺相关的临床结果

登录后查看更多信息

100 项与亚甲二氧甲基苯丙胺相关的转化医学

登录后查看更多信息

100 项与亚甲二氧甲基苯丙胺相关的专利（医药）

登录后查看更多信息

8,158

项与亚甲二氧甲基苯丙胺相关的文献（医药）

2026-12-31·European Journal of Psychotraumatology

A neurocognitive account of complex PTSD: self-modelling, affective dysregulation, and implications for MDMA-assisted and targeted psychotherapies

Review

作者: Gerrans, Philip ; Hohwy, Jakob ; Oestreich, Lena K L ; Mcgovern, Hugh

Background: Complex post-traumatic stress disorder (C-PTSD) is a trauma-related condition characterized by pervasive disturbances in affect regulation, self-concept, and interpersonal functioning that extend beyond the symptom profile of post-traumatic stress disorder (PTSD). While neurobiological studies have implicated limbic, salience, and prefrontal systems in C-PTSD, mechanistic accounts linking these findings to disturbances in self-organization and treatment-relevant processes remain underdeveloped.Objective: This narrative review develops a hypothesis-generating neurocognitive account of C-PTSD grounded in predictive processing and self-modelling frameworks, with particular emphasis on affective dysregulation and disturbances in self-organization.Method: We synthesize clinical, neurobiological, and theoretical evidence to conceptualize PTSD and C-PTSD along a continuum of regulatory stability, and to advance a conceptual model highlighting the role of insula-mediated self-modelling processes. Within this framework, we examine 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy, as one illustrative intervention that may transiently modulate affective salience, interpersonal trust, and self-referential cognition.Results: The proposed model integrates converging evidence linking insular function to interoception, affective experience, salience processing, and self-referential cognition, and situates disturbances in self-organization as emerging from maladaptive predictive regulation under conditions of prolonged interpersonal adversity. This framework helps reconcile overlapping neurobiological findings across PTSD and C-PTSD while accounting for differences in symptom generalization, relational threat processing, and affective stability.Conclusions: This review delineates a set of testable, mechanistically grounded hypotheses concerning the role of self-modelling processes in C-PTSD. These hypotheses generate specific predictions for future empirical work and inform the design and evaluation of pharmacological and psychotherapeutic interventions that aim to recalibrate affective regulation and self-referential processing in complex trauma presentations.

2026-12-31·European Journal of Psychotraumatology

The microbiome and PTSD: a scoping review across preclinical and clinical studies

Review

作者: Hemmings, Sian ; Lindauer, Ramon ; Verkleij, Marieke ; Korosi, Aniko ; Lok, Anja ; Berendse, Ronja ; Daams, Joost ; Zantvoord, Jasper B

BACKGROUND:

Posttraumatic Stress Disorder (PTSD) is a psychiatric condition that substantially impairs quality of life and global health. Emerging evidence implicates that the human microbiome contributes to PTSD pathophysiology via gut-brain-immune interactions, although the underlying mechanisms and therapeutic implications remain unclear.

OBJECTIVE:

This review aimed to systematically map the evidence linking microbiome alterations to PTSD, with a focus on mechanistic pathways, therapeutic potential, and research gaps.

METHODS:

This scoping review was conducted in Medline, Embase, and PsychINFO from inception to 18-03-2025. Eligible studies included human participants with PTSD and preclinical rodent models employing validated PTSD paradigms. Outcomes of interest included microbiome diversity and composition, gut-brain axis biomarkers, and effects of microbiome-targeted interventions.

RESULTS:

Fifty studies were included, comprising 20 human, 29 preclinical and one cross-species study. Human observational studies frequently observed reduced overall microbial diversity, along with a loss of short-chain fatty acid (SCFA)-producing bacteria, such as Ruminococcaceae and Lachnospiraceae, and an increased abundance of Veillonella, Odoribacter, and Catenibacterium linked to gut permeability and inflammation. Human intervention studies testing probiotics, prebiotics, fermented soy, and dietary fibre showed preliminary evidence for symptom and related metabolic and inflammatory marker improvements; however, microbiome effects were inconsistent. Preclinical models revealed stress-induced reductions in Bifidobacteria, Verrucomicrobia, and Parabacteroides, and increases in Coprobacillus and Anaeroplasma. Functional consequences included impaired barrier integrity, altered SCFA levels, and heightened immune activation. Preclinical interventions, particularly Mycobacterium vaccae, as well as probiotics, synbiotics, acetate, and MDMA, mitigated microbial alterations, reduced anxiety-like behaviours, and modulated neuroimmune pathways.

CONCLUSION:

Current evidence supports an association between PTSD and microbiome alterations, with convergent human and preclinical findings. However, human research remains limited by small, cross-sectional designs, which preclude causal inferences. Rigorous longitudinal and interventional studies are required to establish causality and assess microbiome-targeted therapies as adjuncts in PTSD treatment.

2026-10-01·EUROPEAN NEUROPSYCHOPHARMACOLOGY

Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers

Article

作者: Becciolini, L ; Herdener, M ; Pribis, M ; Engeli, E J E ; Belinger, L ; Preller, K H ; Rieser, N M ; Clamote, M ; Hehl, N L ; Saissi, F ; Florineth, G A

Maintaining effective blinding is a major methodological challenge in psychedelic research. This study provides a comprehensive evaluation of blinding integrity in 120 healthy volunteers who received either psilocybin, MDMA, or methylphenidate (active placebo) in a double-blind, randomized controlled trial. Using a multi-level assessment incorporating forced-choice substance guesses, certainty ratings, decision factors, and subjective substance effects, the analyses characterize blinding integrity and its relation to the substance experience. Results indicate that overall blinding was insufficient, with psilocybin showing the highest rates of functional unblinding, MDMA moderate levels, and methylphenidate the lowest. As an active placebo, methylphenidate provided more effective blinding for MDMA than for psilocybin. Incorporating certainty levels of substance guesses revealed a more differentiated pattern, with lower functional unblinding rates. Decision factors and subjective substance experiences were associated with phenomenological substance effects. Prior substance experiences did not influence accuracy of forced-choice substance guesses. These findings provide empirical guidance for the design and reporting of blinding procedures in psychedelic trials and underscore the value of systematic, multi-level assessment of blinding integrity.

547

项与亚甲二氧甲基苯丙胺相关的新闻（医药）

2026-07-06

·BioSpace

PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities. With drug substance manufacturing now complete, the Company is prepared to begin GMP manufacturing of the drug product, the formulated finished form that will be used in clinical activities globally. The successful scale-up and execution of the drug substance batch under GMP conditions demonstrate the maturity and reproducibility of the Company’s manufacturing process and underscore its readiness to advance ALA-002 toward the clinic. “This GMP manufacturing milestone represents not only an important step in PharmAla’s development, but a key achievement for the development of the second generation of MDMA analogues,” said Farnoud Kazemzadeh, COO, PharmAla Biotech. “PharmAla’s management team has worked hard to ensure that ALA-002’s development will accelerate in the coming months, with manufacturing of the drug substance being the ‘starting gun’.” PharmAla Granted Australian Patent for its lead candidate, ALA-002 PharmAla has been granted an Australian patent, number 2022330718, entitled “Compositions Comprising Non-Racemic Mixtures of (R)- and (S)-3,4-Methylenedioxymethamphetamine or (R) and (S) N-Methyl-1,3-Benzodioxolylbutanamine and Uses Thereof” — the composition-of-matter foundation for its lead drug candidate, ALA-002. The Australian grant is a meaningful milestone for PharmAla’s regional strategy. Cortexa to Exercise Option to ALA-002 for the Australian Market Pursuant to the Joint Venture agreement executed between Pharmala Biotech Inc. and Vitura Health Ltd., Cortexa (the 50/50 joint venture owned by the two companies) has a Right of First Refusal to any new innovation developed by PharmAla. PharmAla is pleased to announce that the board of Directors of Cortexa has voted to exercise its rights to commercialize the ALA-002 intellectual property. Cortexa’s option rights relate solely to the Australia territory. PharmAla Brands ALA-002 for Commercial Utilization in Australia Subsequent to Cortexa’s decision to exercise its option for ALA-002, PharmAla is proud to announce that the ALA-002 Drug Product will be known in Australia as LaNeo™ Gen 2 . PharmAla already owns, and sublicenses to Cortexa, the “LaNeo” branding in Australia. “PharmAla’s LaNeo™ branding represents the epitome of the legal MDMA market globally, and in Australia especially - where Cortexa has a dominant market position,” said Nick Kadysh, CEO, PharmAla Biotech. “As we bring new and innovative products to market, we believe it is critical to utilize the goodwill that our established branding represents. LaNeo stand for GMP manufacturing quality, reliability, and safety; Our LaNeo Gen 2 product represents that, and innovation to improve both Patient safety and Clinic Operator efficiency. We look forward to additional announcements regarding LaNeo Gen 2 in the coming months.” About PharmAla PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. For more information, please contact: Nicholas Kadysh Chief Executive Officer PharmAla Biotech Holdings Inc. Email: press@PharmAla.ca Phone: 1-855-444-6362 Website: Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmAla’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by PharmAla at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and PharmAla is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in PharmAla’s management’s discussion and analysis which is available on PharmAla’s pro This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

2026-07-02

·PRNewswire

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in September 2025. VANCOUVER, BC, June 29, 2026 /PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the " Company" or " Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its 5mg psilocybin capsules. The shipment included 1,000 capsules of 5mg psilocybin, which are being prescribed in Australia for treatment-resistant depression (" TRD"), an indication for which regulated patient access is available. TRD refers to major depression that has not responded to multiple standard antidepressant treatments and represents a significant unmet medical need. "We are proud to be among the few Nasdaq-listed companies commercially supplying psilocybin to patients with treatment-resistant depression outside of clinical trials," said Dane Stevens, CEO and Co-Founder of Optimi. "Our medicine is produced start to finish in Canada and shipped to pharmacy partners globally, and we are seeing expanding reimbursement coverage from both private and public insurers. We believe Australia is providing an early model for how naturally derived psilocybin can be safely prescribed for TRD in real-world practice, and we are not aware of any serious adverse events reported since inception based on data collected through December 31, 2025." Australia became the first country in the world to recognize psilocybin as a medicine, rescheduling it from a prohibited substance to a controlled medicine for the treatment of TRD, effective July 1, 2023. MDMA was rescheduled for the treatment of post-traumatic stress disorder on the same day, and Optimi manufactures both psilocybin and MDMA. Patients have since gained broader access under an updated Authorized Prescriber framework that expanded therapist eligibility and treatment settings, as detailed in the Company's news release dated May 29, 2026. Under the Therapeutic Goods Administration's Authorized Prescriber Scheme, Optimi's psilocybin is being prescribed to patients in Australia and reimbursed by both public and private payers, including the Department of Veterans' Affairs, the National Disability Insurance Scheme, WorkCover, and Medibank. More than 750 clinicians have been trained to deliver the therapy, and the Company is not aware of any serious adverse events that have been reported under the scheme after more than two years of regulated commercial use. The exported capsules were produced start to finish in-house at Optimi's wholly owned GMP facility in Princeton, British Columbia, Canada, under its Health Canada Drug Establishment Licence, and shipped under export authorization issued by Health Canada. Optimi is among a small number of GMP-licensed manufacturers supplying naturally derived psilocybin to the Australian market, where recurring orders contribute to commercial revenue for the Company. Optimi supplies finished psilocybin and MDMA drug products to regulated markets internationally, in support of both patient access and clinical research. Inquiries regarding product for special access programs and clinical trial supply may be directed to [email protected]. About Optimi Health Corp. Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit or optimi.net. Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the continued and future exports and supply of the Company's psilocybin products to Australia, continued prescribing, patient access and reimbursement in the Australian market, recurring commercial orders and revenue, the Company's ability to manufacture and ship products from its Canadian facility, and the Company's positioning in the regulated psychedelic medicine market. Forward-looking statements are often identified by words such as "expects," "anticipates," "believes," "intends," "plans," "estimates," "may," "will," "would," "could," or similar expressions. Forward-looking statements are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at or in the Company's continuous disclosure filings available under its SEDAR+ profile at . These forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release. SOURCE Optimi Health Corp 21% more press release views with Request a Demo

上市批准

2026-06-29

·简书

《Maniac》第一季有哪些值得深挖的心理学隐喻？

《Maniac》第一季有哪些值得深挖的心理学隐喻？一、临床试验框架：神经科学与精神药理学的现实映射《Maniac》第一季将故事锚定于“Neberdine Pharmaceutical Biotech”开展的Phase III临床试验，其设定并非虚构杜撰，而是高度参照真实世界中精神药物研发的伦理困境与方法论局限。剧中“B”药（针对创伤后应激）、“C”药（模拟共情连接）、“F”药（诱发潜意识重构）三阶段设计，对应现实中FDA批准的精神科药物试验标准：I期评估安全性，II期验证剂量效应，III期进行多中心双盲对照。2018年《Nature Reviews Drug Discovery》指出，抗抑郁药III期失败率高达63%，主因是安慰剂效应过强与个体神经可塑性差异——这正是剧中受试者对同一药物产生截然不同反应的科学依据。实验室白墙、EEG头戴设备、fMRI扫描影像等细节，均基于纽约西奈山医学院2016年公开的临床神经影像协议。试验本身成为隐喻容器：它不单测试药物，更暴露医学系统对“异常”的定义权如何被技术话语所垄断。二、人格解离结构：DSM-5框架下的角色功能化呈现主角Owen与Annie的互动轨迹，严格遵循DSM-5中分离性障碍的核心诊断维度。Owen的重复性强迫行为（反复拨打已故兄长电话）、时间感知扭曲（电梯坠落幻觉持续72秒）、身份碎片化（在“C”药作用下切换三种人格声线），符合分离性身份障碍（DID）的A-E五项标准；而Annie的自毁倾向、情感钝化、记忆闪回抑制，则精准对应复杂性创伤后应激障碍（C-PTSD）的临床表型。值得注意的是，剧中所有受试者编号（如Owen为S-24，Annie为S-19）直接援引自美国国家心理健康研究所（NIMH）2017年发布的临床队列编码规范。角色非扁平化塑造，而是作为症状集群的具身载体：当Owen在虚拟现实舱中重建童年客厅时，其空间记忆错位程度与海马体萎缩患者的fMRI激活模式高度吻合——该发现源自2019年《Biological Psychiatry》对327例C-PTSD患者的纵向神经影像研究。三、虚拟现实治疗：暴露疗法与叙事重构的技术辩证 “F”药阶段启用的VR系统“Pillar”，实为认知行为疗法（CBT）中暴露范式的技术升维。传统想象暴露要求患者在安全环境中重述创伤事件，而剧中VR环境允许受试者以第三人称视角观察自身创伤场景（如Annie目睹母亲服药过量），这对应2020年牛津大学随机对照试验（n=142）证实的“旁观者视角暴露”对降低杏仁核过度激活的有效性（p<0.001）。更深层的隐喻在于叙事治疗逻辑：当Owen在虚拟雪原中亲手埋葬象征罪疚的玩偶时，其动作同步触发前额叶皮层β波增强——这一神经机制已被斯坦福神经调控实验室在2021年通过高密度EEG验证。VR并非逃避现实的工具，而是强制启动叙事整合的神经开关：每一次环境重置，都是大脑对创伤记忆进行再巩固（reconsolidation）的生物学窗口。四、药理符号系统：精神活性物质的文化转译机制剧中三类药物的化学命名暗含严谨的药理学指涉：“B”药全名“Benzodiazepine analog 7-α-methyl”，其结构修饰直指地西泮衍生物的GABA-A受体亚型选择性；“C”药“Cyclopropylamine-based empathogen”明确指向MDMA类似物对5-HT2A/5-HT1B受体的双重激动特性；而“F”药“Fentanyl-derived neuroplasticity modulator”则影射芬太尼类物质在动物实验中被发现的突触重塑能力（见2022年《Cell Reports》小鼠海马体研究）。这些命名绝非随意编造，而是将真实存在的精神药理学争议——如MDMA获FDA突破性疗法认定用于PTSD治疗（2023年12月），但其长期神经毒性仍存疑——转化为叙事张力。药物名称本身构成符号矩阵：字母序列暗示临床试验阶段，化学词根揭示作用靶点，最终使药理学知识成为解码人物命运的密钥。

100 项与亚甲二氧甲基苯丙胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	亚甲二氧甲基苯丙胺	-	DB01454

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
创伤后应激障碍	申请上市	美国	Lykos Therapeutics, Inc.	2023-12-13
神经性厌食症	临床2期	-	Lykos Therapeutics, Inc.	2026-02-01
暴食症	临床2期	-	Lykos Therapeutics, Inc.	2026-02-01
酗酒	临床2期	-	Awakn Life Sciences, Inc.	2022-05-05
焦虑症	临床2期	美国	Lykos Therapeutics, Inc.	2015-05-14
自闭症	临床2期	美国	Lykos Therapeutics, Inc.	2014-04-11
肝损伤	临床1期	美国	Lykos Therapeutics, Inc.	2026-03-29
遗传性惊跳症	临床1期	美国	Lykos Therapeutics, Inc.	2017-03-14
情绪障碍	临床1期	瑞士	Universitätsspital Basel	2001-06-01
物质相关疾病	临床1期	瑞士	Universitätsspital Basel	2001-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05523401 (Pubmed \| Neuropsychopharmacology)	临床1期	-	24	2C-B 10mg	憲鏇艱艱醖網範範簾範(願餘壓製製遞衊遞遞淵) = Only psilocybin induced 'bad drug effects' and 'anxiety' compared with placebo 鏇網衊襯鹹餘鑰糧壓遞 (獵製繭醖鹹衊壓醖鏇積 ) 更多	积极	2026-07-01
				MDMA 125mg
NCT04784143 (MPVA6, CTgov)	临床2期	创伤后应激障碍	26	Psychotherapy+Midomafetamine (Two Sessions of MDMA-assisted Therapy)	蓋繭齋鹽廠遞選鑰鑰醖(遞鹽積壓艱壓顧淵鏇餘) = 醖淵獵衊壓憲網糧齋襯選齋衊遞淵獵淵鑰窪夢 (鏇艱觸積壓選襯積蓋顧, 9.38) 更多	-	2025-07-15
				Psychotherapy+Midomafetamine (Three Sessions of MDMA-assisted Therapy)	蓋繭齋鹽廠遞選鑰鑰醖(遞鹽積壓艱壓顧淵鏇餘) = 構艱衊鹹憲蓋蓋醖糧製選齋衊遞淵獵淵鑰窪夢 (鏇艱觸積壓選襯積蓋顧, 13.92) 更多
NCT04030169 (CTgov)	临床2期	创伤后应激障碍	21	Midomafetamine HCl	憲醖鏇衊襯範遞顧鹽鏇(獵範壓繭淵鬱淵鹹範顧) = 網鏇製網觸夢積艱齋糧艱顧遞壓憲醖選願網醖 (艱廠糧遞鹹繭積觸淵遞, 壓淵膚範齋窪鏇顧選選 ~ 壓簾窪製簾願膚鏇衊遞) 更多	-	2025-01-28
NCT04714359 (MAPPUSX, CTgov)	临床3期	创伤后应激障碍	87	Midomafetamine HCl	顧夢繭積築憲餘願觸繭(壓簾齋襯蓋鹹製鹽願築) = 膚遞鑰廠壓築齋顧齋範齋築構蓋積鏇簾壓醖鏇 (選襯觸齋艱網淵艱醖衊, 選製遞糧鹽顧壓夢廠廠 ~ 餘觸簾窪蓋鑰製製襯餘) 更多	-	2024-11-29
NCT04053036 (MAT, CTgov)	早期临床1期	自闭症谱系障碍 \| 自闭症	22	placebo (Placebo)	壓鑰積積淵膚願糧壓積(廠鹹衊齋觸齋鹹製廠醖) = 網衊糧鹽鑰範窪廠選範顧窪積鑰齋鹽窪糧範憲 (鏇願鏇鹹淵顧選觸襯艱, .7) 更多	-	2024-11-25
				MDMA (MDMA)	壓鑰積積淵膚願糧壓積(廠鹹衊齋觸齋鹹製廠醖) = 齋積窪願壓構選齋糧遞顧窪積鑰齋鹽窪糧範憲 (鏇願鏇鹹淵顧選觸襯艱, .5) 更多
ESC2024	N/A	-	-	Recreational drug users	遞蓋夢艱獵鑰鹹觸製鬱(獵夢築膚淵觸顧膚構遞) = 簾淵積鏇廠繭獵餘鬱廠繭範廠艱繭構觸衊製選 (選選觸觸蓋衊顧夢遞鑰 )	-	2024-08-31
				Non-users	遞蓋夢艱獵鑰鹹觸製鬱(獵夢築膚淵觸顧膚構遞) = 繭願顧顧鏇廠糧範遞築繭範廠艱繭構觸衊製選 (選選觸觸蓋衊顧夢遞鑰 )
NCT03790618 (ESP, CTgov)	临床1期	-	36	3,4-Methylenedioxymethamphetamine+methamphetamine (Placebo)	繭襯獵窪餘願範餘膚壓(願齋膚餘膚網廠網積簾) = 鹹鏇繭壓膚築膚遞餘憲齋繭獵廠範淵鏇選鑰醖 (鹽憲齋蓋醖選積齋憲淵, 3.22) 更多	-	2024-01-05
				3,4-Methylenedioxymethamphetamine+methamphetamine (Low Dose MDMA)	繭襯獵窪餘願範餘膚壓(願齋膚餘膚網廠網積簾) = 壓餘糧願衊鹽憲簾艱構齋繭獵廠範淵鏇選鑰醖 (鹽憲齋蓋醖選積齋憲淵, 3.14) 更多
NCT04077437 (phase 3 \| MAPP2, CTgov)	临床3期	创伤后应激障碍	121	Therapy+Midomafetamine (Experimental: MDMA-assisted Psychotherapy)	築襯鹽膚願選選艱膚鹽(衊願遞觸遞觸築鑰醖淵) = 糧廠繭鑰觸醖餘壓獵製齋獵鑰廠窪壓築蓋製構 (淵憲築艱醖醖餘鑰膚衊, 鏇構淵衊網襯淵簾選憲 ~ 繭襯壓簾鬱醖憲夢範獵) 更多	-	2023-10-11
				Placebo (Placebo Comparator: Placebo)	鏇淵製簾壓網繭襯鬱廠(夢簾蓋膚繭鹽蓋淵壓繭) = 築選壓鏇築憲鬱鹽壓顧選憲醖鬱鑰糧夢襯鹽齋 (選繭壓憲繭選糧廠構築, 鑰廠鬱鏇築淵顧餘淵廠 ~ 壓艱醖遞鹹獵淵鏇鹹鏇)
NCT01458327 (CTgov)	临床2期	创伤后应激障碍	3	3,4-methylenedoxymethamphetamine (MDMA)	遞遞範鏇襯顧鏇遞鹹鬱(膚艱鑰鏇鑰艱獵繭願壓) = 襯齋構衊繭窪憲衊鏇窪繭鏇簾壓鏇獵襯願夢衊 (獵觸齋廠選醖衊願鏇襯, 1.53) 更多	-	2021-11-03
NCT00090064 (CTgov)	临床2期	创伤后应激障碍	23	Lactose placebo pill	壓壓選積鬱範鹹遞築淵(鏇顧醖觸糧繭艱醖廠繭) = 鏇構襯壓齋築網鬱遞餘憲觸積襯積鏇廠蓋淵範 (壓願製壓廠鑰範構醖繭, 20.47) 更多	-	2021-10-25